We have a diversified clinical late-stage R&D portfolio of repurposed drugs and precision medicines in high unmet need diseases. Our portfolio includes five treatments for six diseases with high unmet medical need, all in clinical stage.

Therapeutic areas of focus are: brain disorders, cardiovascular and inflammatory bowel diseases.

Our lead compound is a PDE4 inhibitor for Cognitive Impairment due to stroke (PSCI) and due to Alzheimer’s disease (MCI due to AD). PSCI and MCI due to Alzheimer’s are early stages of dementia for which no treatment currently exists. Dementia is one of the costliest diseases for society and one of the diseases with highest impact on quality of life for patients concerned.

Inflammatory Bowel Disease (IBD) is our 2nd late stage pipeline project. IBD is a chronic disorder characterized by periods of inflammation of the gastrointestinal tract which result in considerable impairment on quality of life for patients.

Our pipeline consists of 3 precision medicine projects from the network pharmacology concept. The most advanced pipeline project is a triple combination therapy to decrease post-stroke-disability for patients with ischemic stroke, again a chronic disease with high burden to society and no treatment options.
Two other pipeline projects address highly prevalent untreatable cardiovascular diseases; resistant hypertension and chronic heart failure with preserved ejection fraction (HFpEF).